Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

11.8%

2 terminated out of 17 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

18%

3 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed with results

Key Signals

3 with results82% success

Data Visualizations

Phase Distribution

14Total
P 1 (5)
P 2 (6)
P 3 (3)

Trial Status

Completed9
Unknown5
Terminated2
Active Not Recruiting1

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT06764589Active Not RecruitingPrimary

Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral Blood

NCT06105658Phase 2UnknownPrimary

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML

NCT00559091Phase 2CompletedPrimary

A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia

NCT01462578Phase 2CompletedPrimary

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)

NCT01474681Phase 1CompletedPrimary

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

NCT03796390Phase 1UnknownPrimary

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

NCT00061581Phase 2Completed

Experimental Bone Marrow Transplant Protocol

NCT00854646Phase 1CompletedPrimary

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

NCT02255162Phase 1Terminated

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

NCT01167166Phase 1CompletedPrimary

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

NCT01621477Phase 2Terminated

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

NCT00015587Completed

Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study)

NCT02244658Phase 3Unknown

Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia

NCT01188798Phase 3Completed

Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies

NCT01809392Phase 2UnknownPrimary

Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT00152139Phase 3Completed

Stem Cell Transplantation for Patients With Hematologic Malignancies

NCT00155844UnknownPrimary

Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier"

Showing all 17 trials

Research Network

Activity Timeline